Journal
BIOMEDICINES
Volume 10, Issue 5, Pages -Publisher
MDPI
DOI: 10.3390/biomedicines10051130
Keywords
immune checkpoint blockade; TNBC; resistance
Categories
Funding
- Hanyang University [HY-202100000003291]
- National Research Foundation of Korea (NRF) - Korea government (MSIT) [2021R1F1A1062411, 2022R1C1C1011387]
- National Research Foundation of Korea [2022R1C1C1011387, 2021R1F1A1062411] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
Immune checkpoint blockades have greatly improved cancer treatment, but a significant number of TNBC patients do not respond to these therapies, and mechanisms of resistance are poorly understood. This review focuses on biomarkers and recent advances in understanding molecular mechanisms of resistance to ICBs in TNBC.
Immune checkpoint blockades (ICBs) have revolutionized cancer treatment. Recent studies have revealed a subset of triple-negative breast cancer (TNBC) to be considered as an immunogenic breast cancer subtype. Characteristics of TNBC, such as higher mutation rates and number of tumor-infiltrating immune cells, render the immunogenic phenotypes. Consequently, TNBCs have shown durable responses to ICBs such as atezolizumab and pembrolizumab in clinic. However, a significant number of TNBC patients do not benefit from these therapies, and mechanisms of resistance are poorly understood. Here, we review biomarkers that predict the responsiveness of TNBCs to ICB and recent advances in delineating molecular mechanisms of resistance to ICBs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
